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ABSTRACT 
 
 
Bromocriptine, a D2 dopamine receptor (D2R) agonist, is used clinically as a treatment 
for pituitary tumors of a lactotroph origin.  Many questions remain unanswered about the 
mechanism of this effect.  The antiproliferative effect has not been demonstrated in DMS 
53 cell line, a Small Cell Lung Cancer (SCLC).  In this thesis, we have shown that 
treatment with NPA (N-propylnorapomorphine), a dopamine receptor agonist inhibits 
ERK phosphorylation and proliferation in DMS 53 cells.  NPA treatment causes 
significant increases in DUSP-1 (MKP-1), DUSP-4 (MKP-2) and DUSP5 mRNA.  NPA 
treatment also correlates with increases in DUSP5 (hVHR3) protein visualized using 
Western Blot.  These three genes were also induced by treatment with exogenous 
arachidonic acid (AA).  In addition, the NPA mediated increases in these genes was 
inhibited by 5,8,11,14-eicosatetraynoic acid (ETYA) an AA analog and inhibitor of 
downstream activity, suggesting NPA induction of these three genes is AA dependent.  
Ethanol treatment leads to inhibition of the NPA induction of DUSP4 and DUSP5, 
suggesting phosphatidic acid (PA) produced from Phospholipase D (PLD) is involved in 
this induction. 
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CHAPTER 1. INTRODUCTION 
 
 
DOPAMINE 
 
 
Distribution of Dopamine Signaling 
 
Dopamine (DA) is a catecholamine derived from Tyrosine in a two step enzymatic 
process.  The limiting step in this process, catalyzed by L-Dopa Decarboxylase removes 
the carboxyl group from L-Dopa (Nolte 2002). DA neurons are found in the olfactory 
bulb, the hypothalamus and the in the ventral midbrain. Substantia nigra pars compacta 
neurons project through the nigrostriatal pathway to the striatum (London 2002), while 
Ventral Tegmental Area neurons project to a variety of locations throughout the central 
nervous system (Prakash 2006; Sillitoe 2008). Neurons in the Ventral Tegmental area 
project through the mesocortical and mesolimbic pathways to regulate a multitude of 
behavioral functions (Sillitoe 2008). DA neurons in the olfactory bulb are involved in 
processing sensory information from olfactory receptor neurons (Cave 2009). 
Hypothalamic Neurons project to cells through the tuberoinfundibular pathway to the 
pituitary (Prakash 2006; Wojcikowski 2009). 
 
 
Functions 
 
CNS DA signaling regulates mood, cognition, attention, reward, reinforcement of 
addiction, and stress, motor control and neuroendocrine control (Bjorklund 2007; Missale 
et al 1998; Schulz 2007; Sillitoe 2008; Smidt 2003; Wise 2004). In the periphery, DA 
regulates vascular tone, catecholamine release, hormone secretion, renal action and 
gastrointestinal motility (Missale 1998). DA indirectly influences changes in the 
periphery, by regulating circulating growth hormone and triiodothyronine levels 
(Wojcikowski 2009).  
 
 
Epidemiology/Involvement in Diseases 
 
A number of drugs interact with the DA receptor family, including the antipsychotics and 
tricyclic antidepressants. For example, DA antagonists such as Haloperidol are used as 
antipsychotic drugs in the treatment of schizophrenia (Kuroki 2008). DA is implicated in 
a multitude of other diseases such, ADHD (Kieling 2010), Parkinson’s disease 
(Hornykiewicz 2008; Prakash 2006), in addition to reinforcement of addictions to drugs 
and alcohol (Ross and Peselow 2009; Sillitoe 2008). 
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Receptors 
 
DA receptors are classic G-Protein coupled receptors with seven transmembrane 
domains. Five DA receptors exist, which are encoded by distinct genes, D1-D5. DA 
receptors signal to a variety of cellular signaling functions, including activation or 
inhibition of adenylyl cyclase (Stoof and Kebabian 1984), activation of potassium 
conductance (Sasaki and Sato 1987), the inhibition of votage-gated calcium currents 
(Lledo 1992), inositol phosphate production (Mahan 1990), AA metabolism (Kanterman 
1991; Piomelli 1991) and stimulation of PLD (Senogles 2000). DA receptors are grouped 
into two classes based on the ability to activate (D1R-like) or inhibit (D2R-like) adenylyl 
cyclase (Stoof and Kebabian 1984). The various DA receptors also differ in binding 
affinities for agonists and antagonists (Table 1.1) (Missale 1998). 
 
 
D2R Dopamine Receptor Signaling 
 
Activation of D2R DA receptors inhibits adenylyl cyclase (De Camilli 1979; McDonald 
1984), voltage gated calcium currents (Lledo 1992) and activates potassium conductance 
(Einhorn 1991) and stimulates PLD (Senogles 2000).  D2R DA receptors (D2R) exist in 
two different isoforms, D2R Long (D2Rl) and D2R short (D2Rs) a result of alternative 
mRNA splicing (Dal Toso 1989). To date, all tissues which express D2R DA receptors 
express both isoforms, but at different ratios (Mansour 1989; Watson 1990). 
 
 
D2R DOPAMINE RECEPTOR MEDIATED CHANGES IN 
ANTIPROLIFERATION 
 
 
Pituitary 
 
Prolactin secreting pituitary adenomas have been treated clinically using Bromocriptine, 
a D2R agonist for many years (Colao 2002; Melmed 1998; Wass 1979). DA agonists 
have also been shown to reduce tumor mass of pituitary adenomas in patients (McGregor 
1979). Addition of DA agonists has been shown to inhibit proliferation in anterior 
pituitary cells (Pawlikowski 1978) and primary lactotroph cultures (Stepien 1978). The 
antiproliferative effects of DA happen in the presence or absence of serum in the culture 
medium (Florio 1992; Senogles 1994). In contrast, stimulation of proliferation has been 
reported in D2R transfected Chinese hamster ovary (CHO) cells and C6 Glioma cell 
lines. In these cases, the proliferative effect was inhibited with pertussis toxin, indicating 
the involvement of Gi/o family of G-proteins and is most likely mediated by cAMP.  
However, the antiproliferative effect is pertussis toxin insensitive, suggesting another 
signaling pathway is involved (Senogles 2000). 
 
The GH4C1 cell line has been widely used to study the antiproliferative effects of DA.  
This cell line was cloned from a rat pituitary tumor and secretes prolactin and growth  
hormone, mimicking isolated primary lactotrophs in culture (Tashjian 1968). However, 
 3
Table 1.1.  Inhibition Constants for Dopamine Receptor Antagonists and Agonists.   
 
Receptor D1 like D2R like 
 D1R D5R D2R D3R D4R 
 
Antagonists 
      
(+)-Butaclamol ++++ +++ ++++ ND +++ 
Chlorpromazine ++ ++ ++++ +++ +++ 
Clozapine ++ ++ ++ ++ +++ 
Eticlopride - - +++++ ND ++++ 
Haloperidol ++ ++ +++++ +++ ++++ 
Nemonapride ND ND +++++ +++++ +++++ 
Spiperone ++ + +++++ ++++ +++++ 
      
Agonists      
Apomorphine + ++ ++++ +++ ++++ 
Bromocriptine ++ ++ ++++ ++++ ++ 
Dopamine + ++ ++ +++ +++ 
7-OH-DOPAT + ND +++ ++++ + 
Quinpirole - ND + +++ +++ 
 
Note: +++++, Inhibition constant(K)<0.5nM; ++++, 0.5nM<K<5nM;  
+++, 5nM<K<50nM ; ++, 50nM,K<500nM;  + ,500nM<K<5 µM -,K>5 µM; ND, not 
determined; 7-OH-DPAT,7-hydroxy-dipropylaminoetetralin. Modified with permission. 
Missale C, Russle N, Robinson S, Jaber M, Caron M. (1998). Dopamine receptors: from 
structure to function. Physiological Reviews. 78(1):189-220. 
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GH4C1 cells do not endogenously express D2R (Cronin 1980) and thus are unresponsive 
to DA (Malarkey 1977). GH4ZR7 cells (Albert 1990) and GH4-121 cell lines (Senogles 
1994) were created by stably transfecting GH4 C1 cells with the cDNA coding for the 
D2Rs DA receptor. 
 
Bromocriptine (Florio 1992), DA and NPA (Senogles 1994) treatment of the GH4ZR7 
cell line inhibits proliferation, as demonstrated by reduced [3H] thymidine incorporation 
and a reduction in cell number.  
 
One group reported that the reduction in growth correlated with an increase in protein 
tyrosine phosphatase activity and that the reduction of proliferation was inhibited by 
pertussis toxin at concentrations of 180 ng/ml (Florio 1992). Senogles (1994) reported 
that at concentrations of 20 ng/ml pertussis toxin had no effect on the D2R mediated 
antiproliferation. This author also demonstrated complete ADP-ribosylation of Gi/Go by 
this concentration of pertussis toxin. Pertussis toxin insensitivity indicates the 
antiproliferative effect does not require the heterotrimeric Gi/Go family of G Proteins 
(Fields and Casey 1997). Since the D2R mediated signaling effects on inhibition of 
adenylyl cyclase, inhibition of voltage gated calcium channels and activation of voltage 
gated calcium channels are in fact inhibited by pertussis toxin this suggests the existence 
of other D2R mediated pathways.   
 
Phorbol Ester downregulation of Protein Kinase C (PKC) blocked DA inhibition of 
prolactin release in primary lactotrophs (Summers 1985). Thus, PKC was investigated as 
a signaling intermediate in the antiproliferation signaling pathway. In GH4ZR7 cells, 
down-regulation of PKC by phorbol esters and selective downregulation of PKC epsilon 
by Thyrotropin Releasing Hormone abolished D2R inhibition of [3H] thymidine 
incorporation (Senogles 1994) and suggested a PKC intermediate. 
 
Typical isoforms of PKC are activated by DAG. Activation of Phospholipase C, (PLC) 
which generates DAG and inositol phosphate (IP3) by the hydrolysis of (PIP2), was a 
potential source of DAG. However, D2Rs signaling did not stimulate increased inositol 
phosphate metabolism in lactotrophs (Vallar 1990) or GH4C1 cells (Senogles 1994).  
 
Another cellular source of DAG is from PA by the action of PLD. PLD activity was 
stimulated by D2Rs in GH4-121 cells (Senogles 2000). The activation of PLD was 
reported to be dependent on RhoA (Senogles 2003), but independent of PLC activation 
(Senogles 2000).  Treatment of cells with 0.5% Ethanol resulted in inhibition of D2Rs 
mediated antiproliferation in these cells (Senogles 2003), which further implicated the 
role of PLD. 
 
 
Small Cell Lung Cancer (SCLC) 
 
The antiproliferative effect of DA agonists has also been in seen in SCLC, when D2R 
agonists inhibited growth of tumor xenografts of SCLC cell lines NCI-H69 and COR 
L103 in athymic nude mice (Ishibashi 1994). The antiproliferative effect, in response to a 
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DA agonist, was in fact demonstrated through a reduction of [3H]  thymidine 
incorporation as well as reduced cell number in NCI-H69 cells, a clonal SCLC cell line 
(Senogles 2007). 
 
Pituitary cells required transfection of the cDNA encoding the D2R in order to study the 
antiproliferative pathway.  Questions arise about artifacts existing resulting from D2R 
transfection. SCLC cells provide a possible model to study antiproliferation without 
transfection. A SCLC cell line NCI-H69 expresses both the D2Rs and D2Rl isoforms as 
shown by PCR and real time PCR (Cooper and Sprio 2006; Senogles 2007).   
 
Approximately 20-25% of lung cancers were of the small cell variety in 1994 (Chia 
1994).  That number has decreased in the past 30 years (Field and Duffy 2008) and now 
represents about 13% of newly diagnosed lung cancer cases (Puglisi 2010).  Small Cell 
Lung Cancer (SCLC) is an aggressive form of cancer with early local and distant 
metastases (Puglisi 2010).  The prognosis of SCLC cases is poor even with early 
diagnosis.  SCLC responds initially to chemotherapy and radiation, but becomes resistant.  
Due to a high reoccurrence rate and development of drug resistance (Zangemeister-
Wittke and Stahel 1999), only 20-40% of limited diagnoses and 5% of extensive 
diagnoses patients survive greater than two years (Lally 2007; Puglisi 2010). More than 
90% of cases involved patients with a history of smoking (Brownson 1992).   
 
 
POTENTIAL PATHWAYS FOR SIGNALING IN ANTIPROLIFERATION 
 
 
Lipid Metabolism 
 
Activation of the D2Rs stimulates PLD in stably transfected D2Rs transfected GH4C1 
cells, HEK 293 cells (Senogles 2000) and in native NCI-H69 cells (Senogles 2007). PLD 
enzymes respond to many different stimuli including cytokines, growth factors 
neurotransmitters resulting in abundant amount of cellular processes to include 
mitogenesis, oncogenesis and metabolic regulation (Exton 2002). Phospholipase enzymes 
catalyze the hydrolysis of ester or phosphodiester linkages of phospholipids (Morris 
1997). PLD (Figure 1.1) catalyzes the hydrolysis of Phophatidylcholine (PC) resulting in 
the formation of phosphatidic acid (PA) and choline (Exton 2002).  
 
Two form of PLD exist, namely PLD1 and PLD2 (Hammond 1995). PLD1 has a low 
basal activity and is regulated by a number of different factors such as many cytokines, 
hormones, neurotransmitters (Exton 2002). Protein Kinase C along with members of the 
Ras superfamily of low molecular weight GTP binding proteins, particularly ADP  
 
Ribosylation factor (ARF) and RhoA (Hammond 1995; 1997; Kanaho 1996) activatate  
PLD1. PLD2 exhibits a high basal activity (Exton 2002), however is regulated by PKC 
and ARF (Weernink 2007). 
 
PA signaling is responsible for many of the cellular actions resulting from PLD 
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Figure 1.1. Phospholipase Action.  Phospholipase D catalyzes the hydrolysis of 
phosphatidyl choline to phosphatidic acid and choline.  Phospholipase C catalyzes the 
hydrolysis of phosphatidyl inositol species to diacylglycerol and inositol phosphate. 
PLA2 catalyzes the cleavage of diacylglycerol to monoacylglycerol and AA.  
 
 
activation. PA can be further metabolized to DAG through phosphatidic 
phosphohydrolase (PAP) or to lysophosphatidic acid as catalyzed by phospholipase A2 
(PLA2) (Exton 2002). In these cells, PA is involved in many processes to include 
membrane trafficking, actin cytoskeleton remodeling, cell proliferation and cell survival 
(Weernink 2007). AA (5,8,11,14-eicosatetraenoic acid), a 20 carbon fatty acid is  
metabolized through several pathways, including the cycloxygenase (COX) pathway, 
lipoxygenase (LOX) pathway and epoxygenase pathway  (Irvine 1982; Sigal 1991). 
Experimental evidence supports the role of AA in a pathway not associated with classical 
Gi/Go stimulated adenylyl cyclase. D2R have been known to generate AA independent 
of adenylyl cyclase in anterior pituitary cells (Canonico 1989) and in Chinese hamster 
ovary cells (Kanterman 1991; Piomelli 1991). In transfected CHO cells, AA release was 
dependent on PKC, calcium (Piomelli 1991) and cytosolic PLA2 (Piomelli and Vial 
1995). 
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Inhibition of Downstream Signaling from PLD by the Addition of Primary Alcohols 
 
PLD activity is measured by a transphosphatidylation reaction where, in the presence of 
primary alcohols, the alcohols substitute for water in the hydrolysis reaction, forming 
phosphatidyl alcohol product (Morris 1997). Thus, when ethanol is added to cultured 
cells, PLD will form the product, phosphatidylethanol which can be distinguished from 
PA on the basis of its migration on a thin layer chromatography plate. The phosphatidyl 
alcohol is generated instead of the naturally occurring PA and as a result, addition of 
ethanol to cells in culture inhibits downstream PA signaling due to the production of 
phosphatidyl ethanol. 
 
 
Inhibition of ERK Phosphorylation 
 
Unpublished results from our laboratory suggest that agonist-stimulation of D2R 
stimulation in in NCI H69 cells, a SCLC cell line, led to a reduction in phosphorylated 
ERK (pERK) levels.  It was determined by Western blotting with a pERK specific 
antibody, that NPA treatment of cells would result in a reduced immunoreactivity.  In 
addition, lysates from these cells were used in an in vitro kinase reaction and showed that 
the ERK kinase activity was also reduced. This data suggests that either the upstream 
kinase, MEK was inhibited or that a phosphatase was activated. Our laboratory has 
previously demonstrated that MEK activity was not changed by addition of NPA, so we 
focused our attention on the possibility of involvement of ERK specific phosphatases. 
 
ERK 1/2 are members of the MAP kinase family. Mitogen-activated protein kinases 
(MAPKs) constitute a family of proteins central to many cellular functions, including 
proliferation, differentiation, cytoskeletal rearrangement, immune function, stress 
responses and apoptosis. The extracellular signal-related kinases (ERKs) were the first 
MAPKs elucidated and are comprised of p42 and p44 (ERK 1/2) and ERK 5.   The stress 
activated protein kinases (SAPKs) are further broken down into the c-Jun N-terminal 
kinases (JNKs), consisting of (JNK 1, JNK 2 and JNK 3) and the p38 MAPKs (alpha, 
beta, gamma, delta) (Zhou 2004). MAPKs are activated by dual phosphorylation of a T-
X-Y motif, whereby both phosphorylation events are required to activate kinase activity.  
Classic signaling of MAPKs involves a three level cascade where each kinase in the 
cascade is activated through phosphorylation by an upstream kinase (Zhou 2004).  
Signaling occurs through a variety of receptors such as seven transmembrane receptors 
(Caunt 2006) or receptor tyrosine kinases (McCay 2007). 
 
Many questions about the mechanism in which ERKs participate in response to multiple 
stimuli remain unanswered.  While ERK phosphorylation was originally believed to be 
the only determinant required for ERK activation, evidence has shown other factors are 
required (Caunt 2006). The strength, duration of the signal, as well as localization, play 
significant roles in the differential responses to agonists. Epidermal growth factor (EGF)-
induced proliferation depends on transient activation of ERK1/2 in the cytosol, whereas 
nerve growth factor (NGF)-induced differentiation requires a sustained activation and 
translocation to the nucleus (Keyse 2006). 
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Varied cellular responses to different stimuli are due to the number of factors which 
interact with ERK.  A large number of ERK substrates exist, including other kinases, 
phosphatases and transcription factors.  Some of these factors regulate transcription of 
immediate early genes, resulting in quick and dramatic changes in gene expression 
(Caunt 2006).   
 
In addition to many different substrates, a wide variety of upstream activators exist.  This 
effect is compounded as a large number of isoforms exist at all three tiers of the MAPK 
cascade.  The ability to interact with both upstream regulators and downstream targets is 
critical in determining the outcome of MAPK signaling. These interactions depend on 
localization, compartmentalization and scaffolding molecules (Caunt 2006). 
 
Much of the research involving ERK involves proliferation and growth factor stimulation 
and sustained expression of ERK is necessary for progression from G1 to S phase 
(Pouyssegur 2007). In cells lacking growth factor stimulation, ERK is sequestered in the 
cytoplasm by MEK (mitogen activated ERK specific kinase), a MAPKK (Fukuda 2000). 
Following activation, ERK localizes to the nucleus. Different ERK signal duration and 
localization yield different results, however the exact reason for this difference is not 
completely understood.  Activated ERK accumulates in the nucleus, during mid G1 phase 
(Volmat 2001) and initiates transcription of immediate early genes in both mitogenic and 
non-mitogenic stimulation (Pouyssegur 2007). 
 
 
Dual Specificity Phosphatases (DUSPs) 
 
Phosphatase activity acts in opposition of upstream phosphorylation events in the MAPK 
cascade. As we had seen reduced pERK in other cell lines in response to DA agonists, we 
hypothesize that this change may be the result of increased phosphatase activity. The 
MAP Kinase Phosphatases, also known as DUSPs were a potential source of the 
increased phosphatase activity as this family of proteins regulates the MAPK family.  
DUSPs are a family of phosphatases comprised of a C-terminal catalytic domain with 
homology to VH-1 phosphatase of vaccinia virus, a non-catalytic domain, which contains 
two regions with homology to cdc25 phosphatase, and a kinase interaction motif (KIM) 
(Keyse 2006). As MAPK activation requires dual phosphorylation on both threonine and 
tyrosine residues, removal of either phosphate results in reduced MAPK activity.   
 
DUSPs reside in various cellular locations and maintain different specificity for MAPKs 
(Keyse 2006). They are divided into three groups, the nuclear inducible, cytosolic ERK 
specific and cytosolic nonspecific DUSPs.  The nuclear DUSPs include MKP-1 
(DUSP1), DUSP2, MKP-2 (DUSP4) and DUSP5.  Of this group, DUSP5 is the only one 
specific to ERK. The others have activity toward all three MAPKs. The second and third 
group consists of cytosolic DUSPs, further divided by the specificity for MAPKs.  The 
ERK specific DUSPs are DUSP 6 (MKP-3) and DUSPs 7 and 9 (MKP-4), while the 
JNK, p38 specific DUSPs are DUSP 8,10 and 16 (Owens and Keyse 2007; Zhou 2004).  
See Table 1.2 for specificities. 
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Table 1.2.  DUSP Family Members.   
 
Gene MKP Subcellular 
localization 
Substrate preference 
DUSP1 MKP-1 Nuclear JNK,p38, ERK 
DUSP4 MKP-2 Nuclear JNK,p38, ERK 
DUSP2 PAC-1 Nuclear ERK,p38 
DUSP5 Hvh-3,b23 Nuclear ERK 
DUSP6 MKP-3 Cytoplasmic ERK 
DUSP7 MKP-X Cytoplasmic ERK 
DUSP9 MKP-4 Cytoplasmic ERK>p38 
 
Note: DUSPs studied belong to the MAP Kinase Phosphatase family and many have 
additional names.  Listed are other commonly used names for these phosphatases. In this 
thesis DUSP names have been used.  DUSPs are either cytoplasmic or nuclear inducible 
gene. Modified with permission. Owens DM, Keyse SM. (2007). Differential regulation 
of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 26:3203-
13. 
 
 
HYPOTHETICAL PATHWAY 
 
We hypothesize that the D2R mediated antiproliferative effect are the result of signaling 
through PLD.  As shown in Figure 1.2 the agonist activation of results in the activation of 
PLD. We hypothesize that PA is metabolized to AA by either the action of cPLA2 or the 
sequential hydrolysis of PA by PAP and DAG lipase. We hypothesize that AA or a 
product of AA metabolism results in an increase of DUSP expression.  The increase in 
DUSP activity reduces pERK and diminishes proliferation (Figure 1.2).  D2R stimulation 
of PLD in GH4-121 cells, HEK (Senogles 2000) and SCLC cell lines (Senogles 2007) 
has been documented previously. 
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Figure 1.2. Hypothetical Pathway. D2R dopamine receptor induction of dual specificity 
phosphatases leading to reduced ERK 1/2 phosphorylation. 
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CHAPTER 2. MATERIALS AND METHODS 
 
 
CELL CULTURE 
 
Human, SCLC Lung Cancer cells line, DMS 53 cells, (ATCC CRL-2062) are a tumor 
cell line established using cells from a 54 year old caucasian male. These cells are 
adherent cells which grow with epithelial-like morphology (Pettingil 1980). The DMS 53 
Cell line was maintained Waymouth’s MB 752/1 medium (Gibco) supplemented with 
10% FBS (Atlanta Biologicals) and 50 ug/ml Gentimycin. Cell cultures were kept in 5% 
CO2 at 37o C.    
 
Passaging of cells and preparation of cells for experiments was performed as follows. 
DMS 53 cells were grown to confluency in 2-75 cm2 flasks. Media was aspirated and 
cells were washed with 1X PBS. At this point, 1 mL of 0.05% Trypsin/EDTA was added 
to each flask and allowed to incubate until cells began to round up.  Cells were suspended 
in complete media, split 14:1 into 2 – 6 well plates for the experiment, discarding 
remaining cells and media. The other flask was split 2:1 into new 75 cm2 flasks. 
Following the 24 hour timeframe, experiment specific treatments were added. 
 
 
NPA TREATMENT AND CYQUANT NF CELLULAR PROLIFERATION 
ASSAY 
 
Cyquant NF cellular proliferation assay was carried out as recommended by 
manufacturer (Invitrogen). Cells from one 75 cm2 flask were Trypsinized and counted on 
a hemacytometer and serial diluted. Dilutions containing total cell numbers of 10000, 
5000, 4000, 3000, 2000, 1000, 500, 400, 300, 200, 100  cells/well were created in 100 
uL, giving six replicates per dilution. Each dilution was plated to a 96 well plate NPA (1 
µM final) in dissolved in 10 µM HCl, final concentration, or 10 µM HCl as a vehicle 
control were added giving three replications per condition and allowed to incubate 
overnight. Dye binding solution was added and the assay was carried out as 
recommended by manufacturer.  Plates were excited at 485 nm and detection of 
fluorescence was carried out at 530 nm. 
 
 
REAL TIME PCR 
 
 
Concept 
 
The probe and primer combination in the LightCycler480 uses Fluorescence Resonance 
Energy Transfer technology for specificity, where primers specific for the gene in 
question give a large level of specificity. The probes, approximately five nucleotides in 
length, add another level of specificity as only in an area of cDNA where both primer and 
probe bind will result in fluorescence. A reporter and a quencher fluorophore are present 
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on the probe.  When intact, the reporter is quenched and no fluorescence occurs.  When 
polymerase extends from the primer, the probe is removed one nucleotide at a time, 
separating the quencher from the reporter fluorophore, thus enabling fluorescence to be 
observed (Information from Roche Light Cycler Product Guide). 
 
 
Treatment and RNA Isolation 
 
Cells grown in 6 well cluster plates were grown to 70-80% and the media was aspirated. 
Cells were washed with 1X PBS and 3 mL of complete media was added.  Cells were 
allowed to grow in this media for 24 hours in order to partially deplete catecholamines 
present in the serum. At this time, treatments were added for each individual experiment 
and incubated in media at 37o C in 5% CO2. Following the completion of incubation in 
experimental conditions, cells were aspirated, washed, lysed and RNA extracted 
following the RNA II manufactures protocol (Clontech).   
 
RNA was purified by Sodium Acetate and Ethanol Precipitation. Concentration of the 
RNA, A260/280 and A260/230 ratios were determined using the Nanodrop 
spectrophotometer.  RNA integrity was determined using Agilent Bioanalyzer.  RNA 
with 8.0 RNA Integrity Number (R.I.N.) or greater were retained, standardized using 
total RNA (1200 ng), reverse transcribed to cDNA using Transcriptor First Strand 
Synthesis Kit following the manufacturer’s protocol.  cDNA was added to Light Cycler 
480 probes master (Roche)  and Crossing points (CP) were determined using Taqman 
protocol on LightCycler 480.  
 
 
Primer Design 
 
Primers were designed using the Universal Probe Library found at https://www.roche-
applied-science.com/sis/rtpcr/upl/ezhome.html (Roche Diagnostics 1996-2010) (accessed 
February 29, 2008). Suggested primer sequences were compared to reported sequences 
for all eight DUSPs tested. If any primer had less than two mismatches in sequence, a 
separate set of primers was selected and verified. Primers were verified using a real time 
PCR standard curve. cDNA were serial diluted 10 fold, to give known relative 
concentrations. See Tables 2.1 and 2.2 for primer and probes used. 
 
 
Calculations 
 
Cycle number is inversely proportional to initial copy number of cDNA. Copy number 
must reach a threshold before fluorescence reaches logarithmic and linear phases. Each 
cycle doubles the concentration of cDNA, drawing closer to and eventually surpassing 
this threshold. The point at which fluorescence changes enter the logarithmic phase is 
defined as the crossing point (CP).  Determining the exact point is difficult and requires 
some interpretation. In this assay, CP values were calculated from highest 2nd derivative 
or inflection point of the curve.
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Table 2.1.  Left Primer Information.   
 
Gene Accession # Amplicon UPL Catalog 
number 
Probe 
# 
Sequence 5' to 3' Length mRNA 
position 
Begin End 
DUSP1 NM_004417.2 64 04688643001 65 CGA GGC CAT TGA CTT CAT 
AGA 
21 962 982 
DUSP2 NM_004418.2 91 04688040001 44 GAC TCC AGG GCT CCT GTC 
TA 
20 569 588 
DUSP3 
 
NM_004090.2 112 04687639001 30 CGG ATC TAC GTG GGC AAC 18 160 177 
DUSP4 NM_001394.5 87 04686900001 17 TGC ATC CCA GTG GAA GAT 
AA 
20 1120 1139 
DUSP5 NM_004419.3 93 04685024001 5 ACA AAT GGA TCC CTG TGG 
AA 
20 929 948 
DUSP6 NM_001946.2 112 04688651001 66 CGA CTG GAA CGA GAA TAC 
GG 
20 789 808 
DUSP7 NM_001947.2 96 04685130001 14 CCC ATC TCT GAC CAC TGG 
AG 
20 796 815 
DUSP9 NM_001395.1 103 04687949001 36 CAC TAC AAG CAG ATC CCC 
ATC 
21 864 884 
DUSP14 NM_007036.2 81 04686959001 22 GCA CAC TGG ACT CTT GAG 
GAA 
21 182 202 
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Table 2.2. Right Primer Information.   
 
Gene Sequence 5' to 3' MW Length mRNA 
position 
Begin End 
DUSP1 
 
CTG GCA GTG GAC AAA CAC C 5806.8 19 1007 1025 
DUSP2 
 
GCA GGT CTG ACG AGT GAC TG 6198.1 20 640 659 
DUSP3 
 
TGT TGA CGT GCA TGA AGG A 5907.9 19 253 271 
DUSP4 
 
GCA GTC CTT CAC GGC ATC 5435.6 18 1189 1206 
DUSP5 
 
CCT TTT CCC TGA CAC AGT CAA 6301.1 21 1001 1021 
DUSP6 
 
TTG GAA CTT ACT GAA GCC ACC T 6694.4 22 879 900 
DUSP7 
 
CAG GAC ACC ACA CTT GG 6062.0 20 872 891 
DUSP9 
 
CGC AGT TCT GGG ACA AGG 5564.7 18 949 966 
DUSP14 
 
CGG CAA GAC CAG AGT GTT TT 6157.0 20 243 262 
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A grouping forms for each dilution of cDNA (Figure 2.1) with the full concentration on 
the left and each successive, 10 fold, dilution causes the shifting of the curve to the right 
approximately 3.32 cycles (Equation 2.1).   
 
 Log2 10=3.32 Equation 2.1 
 
This equation was the basis for the concentration curve. Determining the difference 
between the actual changes in molecules per cycle gives the efficiency of the reaction. As 
the real time PCR progresses, each cycle doubles the concentration of cDNA. Efficiency 
of this curve was measured based on the ability to double with each successive cycle.  
Efficient primers which double each cycle would change 3.32 cycles between each ten 
fold dilution.  A linear concentration curve was generated, where the log of the 
concentration was plotted on the x-axis and the corresponding CP value plotted on the y-
axis (Figure 1.3). Efficiency can be determined based on the reverse operation of 
Equation 2.1 as shown in Equation 2.2 (Bustin 2004). 
 
 Efficiency=10 (-1/slope)-1 Equation 2.2 
 
Efficiency of this curve was measured based on the ability to double with each successive 
cycle.  If the efficiency was below 1.8, alternative primers were selected. Figure 2.2 
shows the standard curve for DUSP1.  
 
Change in expression was determined using the ∆∆ CT method, where  the slope of the 
efficiency curve was assumed to be two. Triplicate CP values were determined and 
averaged for the gene of interest and cyclophilin D standard for each cDNA.  Delta CT 
was determined by subtracting the CP Value of Cyclophilin from that of each gene, 
giving every sample (one well from the six well plate) a Delta CT value. Because 
concentration doubles each cycle, subtracting CP values is the same as subtracting the 
logarithm of the concentration or dividing the concentrations.   ∆∆ CT was then 
determined by subtracting the CP values determined from vehicle control from those of 
determined from cDNA derived from experimental conditions. If ∆∆ CT was negative, 
meaning fold change was positive, Equation 2.3 was used to determine fold change 
(Bustin 2004).  
  
 Fold Change=2(-∆∆ CT)-1  Equation 2.3 
 
In the cases where ∆∆ CT was positive, Equation 2.4 was used to determine mean fold 
expression change. 
  
 Fold Change=-2 (∆∆ CT)+1  Equation 2.4 
 
 
Statistics 
 
Determination of ∆∆ CT statistic represents an n value of one. Thus, one cell culture well, 
containing the experimental treatment was compared to another well containing the 
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Figure 2.1. Real Time PCR Amplification Curves. Figure shows the fluorescence 
changes of DUSP1 concentration curve.  Successive ten-fold serial dilutions of cDNA 
were made.  Identical concentrations group together, giving similar Crossing point (CP) 
values.  CP value is the theoretical point where fluorescence leaves the baseline, but is 
determined by the point of highest 2nd derivative. Change in expression is proportional to 
the change in CP values. 
 
 
 
 
 
    
 
Figure 2.2.  Standard Curve for DUSP1.  This is an example of the curves used to 
determine efficiency of primers in real time PCR. 
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control for an n value of one.  One set of RNA and subsequently one cDNA was 
generated from each well, thus each number (n) was a separate experiment. In order to 
prevent a batch effect, real time PCR was performed over the course of several days.  
Each cDNA from treated cells was only compared to those of controls generated on the 
same day, however. Hypothesis tests where NPA was compared to vehicle were 
performed to obtain fold change data. A value of zero represented the null hypothesis.  
An unpaired students t-test was performed comparing fold change over vehicle to the null 
hypothesis of zero change. For inhibition experiments (AA, Ethanol and ETYA) 
hypothesis testing was carried out using a two-tailed unpaired t-test.  
 
 
Selection of Cyclophilin D as a Reference Gene 
 
Prior to any real time PCR analysis, cells were treated with appropriate concentration of 
drugs of interest. For example 1 µM NPA, 100 µM NPA or Vehicle was used in NPA 
experiment. Three individual experiments were performed and RNA was extracted and 
reverse transcribed to cDNA. As an effective standard, we sought out a gene of which 
expression did not change following application of drugs of interest. Real time PCR was 
performed in triplicate for each cDNA using primers for six different human 
housekeeping genes including Cyclophilin D, beta actin, beta 2 microglobulin, beta 
glucuronidase, TATA box binding protein, transferin receptor. Expression of each gene 
was compared to concentration of the drugs of interest and correlation coefficients and R 
squared values were calculated for each gene. None of the housekeeping genes analyzed 
had greater than 0.15 R squared value. The Cyclophilin D gene at R squared equal to 0.04 
was the lowest of any of these genes, indicating that this gene changed very little in 
response to drug addition. Thus, cyclophilin D was selected as the reference gene used to 
standardize the Real time PCR experiments. 
 
 
WESTERN BLOT 
 
DMS 53 cells were split into 2 – 6 well plates, plated at a density of 105 cells/well and 
grown to 70-80% confluency at which point the media was aspirated, cells were washed 
and complete media was added. Drugs of interest were added and cells were lysed. 
At the time of lysis, cells were aspirated, washed with PBS. Cells were kept on ice, where 
they were lysed using with 600 uL ice cold RIPA buffer (25 mM Tris-HCl pH 7.6, 150 
mM NaCl, 1% NP40, 1% sodium deoxycholate, 0.1% SDS), containing protease inhibitor 
cocktail (P8340 Sigma, containing AEBSF for serine proteases, Aprotinin for serine 
proteases, Bestatin hydrochloride for aminopeptidases, E-64 for cysteine proteases, 
Leupeptine hemisulfate salt for serine and cysteine proteases and Pepstatin A for acid 
proteases) for 15 min.  Following this incubation, lysates were passed several times 
through a 21 gauge needle and once again placed on ice for 30 minutes.  Lysates were 
pelleted via centrifugation at 10000 X G. Supernatents were removed and stored 
overnight at -20o C and the pellets were discarded. 
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Protein concentrations were determined using the Bradford method (1976) with Bradford 
Reagent (BioRad) using Bovine Serum Albumin as the standard. Samples were boiled 5 
min and mixed with 2X sample buffer (Laemmli 1970). Routinely a total protein 
concentration of 50 ug was loaded and subjected to electrophoresis through a 12% SDS-
PAGE (Laemmli 1970) gel at 100 V. Proteins were transferred to nitrocellulose 
membrane by blotting at 110 V for 1 hr. Membranes were blocked overnight in Blotto A 
(5% nonfat dry milk in, 0.01% Tween 20).  Membranes were incubated in primary 
antibody for 1 hour at ambient temperature, washed 3 X 15 minutes in PBS-T (1 X PBS 
+ 0.01% Tween 20).  Primary antibody dilution used were Rabbit IgG polyclonal anti-
DUSP5 (281-295) (sigma # D8819) 1:1000 or  anti-pERK at 1:1500 (Abcam #ab65142), 
anti-Beta Actin mouse monoclonal IgM (Oncogene Sciences) at 1:1200. The secondary 
Ab used were Goat anti rabbit  1:1000) Horseradish Peroxidase (HRP) Conjugate 
(Biorad) for  DUSP5 and pERK.  For actin a secondary HRP conjugate (Oncogene 
Sciences #JA1200) was used (1:1500). Membranes were visualized using Enhanced 
Chemiluminescence Substrate (Western Lightning).  
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CHAPTER 3. RESULTS 
 
 
D2R DOPAMINE RECEPTOR MEDIATED ANTIPROLIFERATION IN DMS 53 
CELLS 
 
 
Experimental Reasoning 
 
The D2R mediated antiproliferative effects have been well established in D2R transfected 
lactotroph cells, HEK cells and native NCI-H69 SCLC cell lines.  NPA addition to all of 
these cultures consistently results in reductions in [3H] thymidine incorporation and 
concomitant reductions in cell numbers.  We chose to characterize DMS 53 cells, which 
form a monolayer as opposed to NCI-H69 cells, which are suspension cells. We needed 
to confirm that D2R stimulation indeed resulted in the antiproliferative pathway in DMS 
53 cells. We assessed changes in proliferation following addition of NPA, a D2R agonist, 
using the Cyquant Cell Proliferation Assay (Invitrogen). 
 
 
Results of D2R Mediated Antiproliferation 
 
The proliferation assay confirmed preliminary results that NPA treatment resulted in a 
reduction in proliferation and cell number (Figure 3.1). The Cyquant assay measures the 
DNA present in cells and is used as a reliable measure of cell number. Results of this 
assay revealed a 27% reduction in proliferation (p<0.001) with 1 µM NPA addition 
overnight at 10000 cells plated (Figure 3.1).  Significant reductions in fluorescence of 
36%, 14% and 31% were witnessed when 5000 (p<0.001), 4000 (p<0.05) and 2000 
(p<0.05) cells were plated respectively. Mean fluorescence levels decreased in cells 
treated with NPA.  As shown, the relative fluorescence changed with cell number, which 
shows this assay is linear over a large range of cell numbers (500-10,000) used in this 
experiment. The reduction in proliferation shown in this assay confirmed results observed 
in our laboratory, using other methods such as [3H] thymidine incorporation or counting 
of cell number after Trypan blue exclusion staining.  Overall, this experiment 
demonstrated that the DMS 53 cells, a SCLC cell line, responds to treatment with NPA, a 
D2R agonist by decreasing proliferation. 
 
The results seen here demonstrate that NPA a DA agonist leads to reduction in 
proliferation in the SCLC cell line, DMS53. The 27% reduction in proliferation was 
modest; however it was performed in a relatively short time period of 4 hours. Changes in 
proliferation were confirmed with changes in cell count performed with a hemacytometer 
(Data not shown).  The reduction in proliferation generated in this assay is routinely less 
than that observed with [3H] thymidine incorporation (about 50%) in our laboratory 
(Senogles unpublished). 
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Figure 3.1.  NPA Inhibition of Proliferation in DMS 53 Cells. Total cell numbers were 
plated as indicated above and treated in the presence (squares) or absence of NPA 
(circles) overnight prior to the detection of fluorescence.   
 
 
Discussion of D2R Mediated Antiproliferation 
 
The Cyquant cell proliferation assay uses a permeant Cyquant GF dye. The fluorescent 
dye is enhanced when binding to cellular nucleic acids and incorporates to DNA when 
cells are dividing. The changes in cell number correlate well with those seen in [3H] 
thymidine incorporation assays (Jones 2001). As a result, changes in fluorescence should 
closely correlate with changes in proliferation, as this method is monitoring DNA content 
and hence cell number. 
 
NCI-1876 cells were also assayed and showed no significant changes in proliferation or 
signaling in response to NPA as revealed by Cyquant assay (data not shown). This is an 
appropriate negative control for experiments as these cells express D2R dopamine 
receptors but are refractory to signaling by DA agonists (Senogles, unpublished 
observations). 
 
Several methods could have been employed in order to generate greater changes in 
proliferation. The assay might have been optimized by determining the time of maximum 
change in proliferation, by determining fluorescence at 12 hours, 18 hours, 24 hours and 
36 hours. In addition, cell synchronization might augment the changes in proliferation. 
Optimization of the effects likely would evoke similar changes to those seen in other DA 
responsive cells and tissues such as anterior pituitary cells (Pawlikowski 1978) primary 
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lactotroph cultures (Senogles 1994; Stepien 1978) and SCLC cells and tissues (Ishibashi 
1994; Senogles 2007). 
 
Previous results from this laboratory suggest that this effect is a D2R specific 
phenomenon. NPA as a DA agonist has a higher specificity for D2R like receptors, but 
does not differentiate well between D2R and D3 isoforms. SCLC cell lines have been 
assayed using RT PCR using probes specific for DA receptor subtypes. In NCI-H69 cells 
(Senogles 2007) and DMS 53 (Senogles unpublished) cell lines, both forms of D2R 
receptors were present, but other D2R like receptors, such as D3 were not detectable. 
 
 
D2R RECEPTOR STIMULATED REDUCTION OF pERK 
IMMUNOREACTIVITY IN DMS 53 CELLS 
 
 
Experimental Reasoning 
 
Treatment of lactotroph cells with a D2R agonist has been reported result in a reduction 
of TRH stimulated pERK (Banihashemi and Albert 2002).  In an SCLC cell line, NCI 
H69, our laboratory has demonstrated that treatment with NPA will result in a reduction 
of pERK immunoreactivity and in ERK kinase activity (Senogles, unpublished 
observations). These results have yet to be confirmed in the DMS 53 cell line.  As a 
result, we wanted to investigate changes in ERK phosphorylation in these cells before 
and after treatment with NPA. Cells were treated with 1 µM NPA in 10 µM HCl or with 
vehicle containing a final concentration of 10 µM HCl and incubated for four hours prior 
to lysis. 
 
 
Results of pERK Western Blot Analysis 
 
As shown in Figure 3.2, treatment with NPA decreased the total amount of 
phosphorylated ERK in DMS 53 cells. This result is in agreement with results previously 
observed GH4ZR7 in NCI-H69 cells (Senogles unpublished observations). Stripping of 
the blot followed by re-probing with an antibody to actin showed no change in actin 
expression. The phosphorylation of ERK was changed over 4 hours, but the protein 
expression probably did not change as actin protein levels were constant.  
 
 
Discussion of pERK Western Blot Analysis 
 
The results here demonstrate pERK immunoreactivity changed following the addition of 
NPA and suggest that pERK levels decrease in response to treatment with D2R agonist.  
Actin was used as a loading control for this blot, and the amount of actin did not change 
over time. However, we remain uncertain that DA agonist addition was not decreasing 
total ERK levels as well. Typically, pERK blots are reprobed for total ERK using a pan-
ERK antibody which would determine total ERK.  
 22
 
 
 
Figure 3.2.  pERK Immunoreactivity following NPA Treatment.  DMS 53 cells were 
treated with 1 µM NPA  for four hours. Cells were harvested and lysates were subjected 
to SDS-PAGE and Western Blot was performed using a polyclonal anti-pERK antibody. 
The blot was visualized with enhanced chemiluminescence. 
 
 
However, we should still investigate an exact timeline to determine the point of 
maximum change in pERK.  In NCI-H69 cells pERK levels decrease with time of NPA 
treatment (Senogles unpublished observations). This result suggests either a reduction of 
MEK activity or an increase in phosphatase activity. Our laboratory has demonstrated 
that MEK kinase activity does not change in response to DA agonists (Senogles 
unpublished observations). Thus, the reduction in phosphorylation is likely the result of 
greater phosphatase activity. We chose to investigate the potential role of phosphatases in 
this effect.  Members of the DUSP family exhibit varied specificities of MAPKs and 
ERK specifically. We chose to identify members of this family through real time PCR.  
Real time PCR analysis would enable us to quickly identify which DUSP changed with 
DA agonist addition. 
 
 
SIGNIFICANT ELEVATION OF DUSP1, DUSP4 AND DUSP5 EXPRESSION 
FOLLOWING NPA TREATMENT 
 
 
Experimental Reasoning 
 
Unpublished results from our laboratory suggested that ERK phosphorylation and kinase 
activity was decreased in response to D2R agonist treatment (Senogles, unpublished 
observations). We wanted to determine what was leading to these changes. The 
laboratory had previously demonstrated that the reduction in ERK phosphorylation was 
not due to decreased MEK activity which would result in lower ERK phosphorylation 
(Senogles unpublished). In vitro kinase assays using a recombinant ERK as substrate, 
demonstrated that treatment of cells with NPA did not result in a decrease of MEK 
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activity (Senogles, unpublished observations). As ERK phosphorylation can be regulated 
either by upstream kinases (MEK) or downstream phosphatases, we chose to investigate 
the involvement phosphatases in this phenomenon. Our cells are growing in media 
supplemented with fetal bovine serum. As a result, the cells are actively proliferating in 
response to growth factors present in the sera. Our hypothesis is that NPA treatment turns 
on a signaling cascade which results in the change of expression or activity of a 
phosphatase which results in ERK becoming dephosphorylated and leading to a decrease 
in proliferation. In our hypothesis, members of the DUSP family of proteins are 
potentially important regulators of ERK phosphorylation and we have chosen to 
investigate the effect of NPA on DUSP expression in DMS 53 cells.  
  
As we showed in our hypothetical pathway in Figure 1.2, AA may play a role in the 
antiproliferative effect by D2R agonists. As summarized previously, agonist treatment of 
D2Rs transfected CHO cells resulted in release of AA (Piomelli 1991). In addition, there 
is evidence from another laboratory which is relevant. In Vascular Smooth muscle cells, 
AA stimulates increases in DUSP1 expression with subsequent changes in protein levels 
(Metzler 1996). This increase in DUSP1 results in a concomitant reduction of 
proliferation. It is our hypothsis that D2R stimulated signaling may result in AA release 
which results in changes in DUSP expression. 
 
Thus, we wanted to determine the expression changes of several DUSP genes following 
D2R receptor stimulation with NPA in the SCLC cell line, DMS 53. Gene expression 
data for eight different DUSPs were evaluated using real time PCR analysis. DMS 53 
cells were treated with NPA for the following intervals:1 hr, 2 hrs or 6 hrs. Controls were 
treated with vehicle: 10 µM HCl. See Materials and Methods for details of RNA 
extraction, reverse transcription and discussion of real time PCR. 
 
 
Result of NPA Treatment Addition to DMS 53 Cells 
 
DUSP1 
 
A comparison of vehicle and NPA treated DMS 53 cells revealed significant increases in 
DUSP1 (MKP-1) at 1 hr, 2 hrs and 6 hrs (Figure 3.3). All of the real time PCR data were 
standardized using cyclophilin as a control gene. We had shown that cyclophilin was the 
least variable of all of the housekeeping genes. At 1 hr, 1 µM NPA treatment led to 0.18 
fold increase (n=18, p<0.01) of DUSP1. At 2 hrs, DUSP1 expression was elevated 0.57 
fold compared to vehicle (n=60, p<0.001), while at 6 hrs change in expression was at the 
highest with a 0.63 fold increase (n=49, p<0.001) (Figure 3.3). These results 
demonstrated a time dependent increase in DUSP1 expression following NPA treatment.  
 
DUSP4  
 
NPA treatment treatment brought about a marginal reduction in DUSP4 (0.16 fold) at 1 
hr (n=13, p<0.05). However, at later time points and with larger sample sizes, increases  
were seen. DUSP4 expression increased with NPA treatment 0.11 fold at 2 hrs (n=70, 
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Figure 3.3.  Real Time PCR Analysis of DUSP1 Expression in DMS 53 Cells 
following Addition of NPA, a D2R Agonist. All samples were standardized using 
cyclophilin D.  The fold change is calculating taking the NPA treated samples divided by 
the vehicle.  A baseline of zero indicates no change compared to vehicle control. 
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 p<0.001) and was at a maximum of 0.17 fold increase at 6 hrs (Figure 3.4). 
 
DUSP5 
 
Significant increases in DUSP5 were seen at 2 hrs with a 0.26 fold increase over vehicle 
(n=66, p<0.001) following D2R stimulation with NPA (Figure 3.5).  DUSP5 levels 
increased even more at 6 hrs, reaching a 0.46 fold increase (n=63, p<0.001). These results 
demonstrate a significant time dependent increase in DUSP 5 expression after NPA 
treatment. 
 
DUSP2  
 
DUSP2 (Figure 3.6) demonstrated small changes in expression. While changes were 
evident, these small changes appeared to achieve significance due to repetition.  
 
Other DUSP Family Members 
 
Other DUSP family members were evaluated for changes in expression following NPA 
treatment of DMS 53 cells.  Shown (Figure 3.7) are the results for DUSP 3, 6, 7, 9 and 14 
after treatment for 1, 2 or 6 hours with NPA. For the sake of comparison, the previously 
shown results for DUSP 2 are displayed. The expression of DUSP 3, 6, 7 and 9 does not 
rise over 0.2 fold compared to vehicle controls. While these measurements have 
significance due to the large number of repetitions, the changes observed are not large. 
DUSP 14 showed changes in expression with NPA treatment at 2 and 6 hours which were 
over 0.3 compared to vehicle control. 
 
 
Discussion of NPA Addition to DMS 53 Cells 
 
Real time PCR revealed statistically relevant increases in DUSPs 1, 2, 4, 5, 6 and 14.   
We believe some of the small variations observed (between 0.2 to -0.2) represent the 
experimental variation caused by evaluation of real time PCR.  At this level of change, it 
is difficult to determine whether any actual change in mRNA is occurring.  While 
statistical significance was reached for DUSPs 2, 4, 6, 14 the minor levels of change are 
close to those seen in cases of statistical variation. The reliability and biological 
significance of the changes seen in these genes is questionable.  In order to maximize the 
reliability of this assay, the experiments were performed on multiple days.  
 
Increases in DUSP1 and DUSP5 were evident as early as 2 hours and remained elevated 
until 6 hours. These increases tripled the estimated experimental variation and the 
changes in these two genes occurred consistently. 
 
While statistically significant, the biological relevance of these minor changes in mRNA 
are in question.  Do these minimal changes represent actual changes in genes expression?  
Are the changes large enough to result in subsequent changes in protein levels? The  
increases in mRNA seen were relatively minor and increased transcription may be the 
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Figure 3.4. Real Time PCR Analysis of DUSP4 in DMS 53 Cells following 
Treatment with NPA. All samples were standardized using cyclophilin D.  The fold 
change is calculated by taking the NPA treated samples divided by the.  A baseline of 
zero indicates no change compared to vehicle control. 
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Figure 3.5.  Real Time PCR Analysis of DUSP5 in DMS 53 Cells following 
Treatment with NPA.  All samples were standardized using cyclophilin D.  The fold 
change is calculated by taking the NPA treated samples divided by the vehicle.  A 
baseline of zero indicates no change compared to vehicle control. 
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Figure 3.6.  Real Time PCR Analysis of DUSP2 in DMS 53 Cells following 
Treatment with NPA.  All samples were standardized using cyclophilin D.  The fold 
change is calculated by taking the NPA treated samples divided by the vehicle. A 
baseline of zero indicates no change compared to vehicle control. 
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Figure 3.7.  Real Time PCR Analysis of DUSP Family Members in DMS 53 Cells 
following NPA Treatment. All samples were standardized using cyclophilin D.  The 
fold change is calculated by taking the NPA treated samples divided by the vehicle.  A 
baseline of zero indicates no change compared to vehicle control.  The data for  DUSP1 
and DUSP5 (Figure 3.3 and 3.5 are shown again for a comparison). 
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source. Instead, decreased degradation of mRNA may lead to these changes. In order to 
determine which effect is occurring, NPA induction while halting transcription could be 
analyzed. If halting transcription inhibits the NPA induction of the DUSP genes, the 
induction is likely occurring through increased transcription. Three of the genes increased 
in this assay, DUSP1, DUSP4 and DUSP5, are all nuclear-inducible genes. While the 
changes are modest, the fact that primarily putative inducible DUSPs are involved 
suggests that actual increased expression of these genes is more likely.  If degradation 
was occurring, it would possibly affect both classes of genes equally. 
 
In order to determine if subsequently protein levels were being increased, we wanted to 
assess these changes through Western Blot. Real time PCR results revealed the greatest 
increases of mRNA in DUSP1 and DUSP5, as result we decided to investigate these 
genes. Preliminary results from DUSP4 (MKP-2) western blots showed DA dependent 
increases (Senogles unpublished). This information, together with real time PCR results 
for DUSP4, led us to further investigate this gene as well. NPA treatments for these all 
three of these genes, which were used as controls in later real time PCR experiments, 
consistently resulted in increases in mRNA.   
 
 
NPA INCREASES IN DUSP5 AS REVEALED BY WESTERN BLOT 
 
 
Experimental Reasoning 
 
As we had observed increased mRNA expression for DUSP1, DUSP4 and DUSP5 and 
we wanted to determine if protein levels were also changing.  Previously, western blots 
were performed, which had demonstrated increases in MKP-2 (DUSP4), but none for 
MKP-1 (DUSP1) (Senogles unpublished). Due to technical difficulties with 
commercially available antibodies and time constraints, we were unable to evaluate all of 
these proteins for this thesis by Western Blot analysis.  Due to the consistent changes in 
DUSP5 expression after NPA treatment we chose to investigate changes in DUSP5 
protein expression.  DUSP5 also has a high specificity of ERK and overexpression has 
been known to reduce ERK phosphorylation (Owens and Keyse 2007). DUSP5 anchors 
ERK in the nucleus, maintaining ERK in a dephosphorylated state and leads to a 
reduction in proliferation (Keyse 2005). 
 
 
Result of DUSP5 Western Blot Analysis 
 
NPA stimulation of DMS 53 with 1 µM NPA for 2hours and 6 hours brought upon 
increases in DUSP5 protein over 10 µM HCl as a vehicle control, as revealed by western 
blot analysis with a DUSP5 specific antibody (Figure 3.8). These changes were 
reproducible and cell types specific. Marked increases in DUSP5 were observed 
compared to 10 µM HCl in DMS 53 cells, but not SCLC NCI-1876 cells (Figure 3.9).   
NCI-1876 cells are unresponsive to the effect of DA and are a negative control (Senogles 
unpublished observations). 
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Figure 3.8.  Western Blot of DUSP5 Protein Expression Time Course after 
Treatment with NPA.  DMS 53 cells were treated in the presence and absence of 1 µM 
NPA for the times indicated.  Lysates were prepared from these cells and subjected to 
SDS-PAGE and Western blotting.  The blots were visualized with Anti-DUSP 5 antibody 
and chemiluminescence.  The blot was stripped and reprobed with anti-actin antibody. 
 
 
 
 
 
 
 
 
 
Figure 3.9.  Western Blotting of NPA Induction of DUSP5 Using NCI-1876 Cells as a 
Negative Control. DMS 53 cells and NCI-1876 cells were treated with 1 µM NPA for 2 
hours. Lysates were prepared from these cells and subjected to SDS-PAGE and Western 
blotting.  The blots were visualized with Anti-DUSP 5 antibody and chemiluminescence. 
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Discussion of DUSP5 Western Blot Analysis 
 
The expression of DUSP5 proteins increased the largest at two hours (Figure 3.8) with 
more modest increases observed at 1 hours and 4 hours. At 2 hours the intensity density 
of the Actin control also remains consistent. As expected, no increase was seen in NCI-
1876 cells, which do not respond to DA by reducing proliferation or signaling to adenylyl 
cyclase or PLD. Protein concentrations levels were standardized prior to electrophoresis 
and western blot analysis to minimize variation.   
 
Other western blots of Actin protein suggest that NPA does not stimulate change in actin.  
However, a control where the DUSP5 blot in Figure 3.9 was stripped and reprobed for 
Actin or other housekeeping protein is necessary for confirmation.  
 
We were still left with questions about the mechanisms leading to the increase in DUSP5 
protein and how these changes affect ERK phosphorylation and proliferation. NPA 
induction of DUSP5 protein was greatest at 2 hours. Real time PCR revealed the greatest 
increases between 2 hours and 4 hours. The quality of the time course for the western blot 
does not give enough information about whether the protein levels remain elevated 
between 2 hours and 6 hours. This timeframe is important because the pERK changes 
were seen at 4 hours. In NCI-H69 lines our laboratory reported that pERK was reduced 
prior at times longer than hour suggesting this effect occurs very quickly.   
 
Further analysis of both proteins should be carried out by stripping and reprobing the 
same western blot to further correlate the times. DUSP5 may lead to an overall reduction 
in ERK phosphorylation levels. In addition, DUSP5 might reduce ERK phosphorylation 
in the nucleus, which might not be detectable by analyzing total pERK levels. It has been 
reported that DUSP5 anchors ERK in the nucleus and isolates ERK cytosolic kinases and 
targets (Keyse 2005). Localization is an important factor in how ERK signals. 
Determining how pERK localization correlates with that of DUSP5 is an important next 
step in understanding the pathway for D2R mediated proliferation. Also, an assay to 
determine if D2R signaling generates increases in phophatase activity would help to 
determine that DUSP activity is leading to reductions in pERK. 
 
While only correlations, these results suggest that D2R activation results in increases in 
DUSP5 mRNA and protein, and putatively leads to reduced ERK phosphorylation. Much 
information about the D2R signaling pathway has been determined in other cell lines.  
We sought to determine the intermediates leading to the increased DUSP5 expression. In 
NCI-H69 cells, the D2R mediated antiproliferative effect was reported to be mediated by 
PLD (Senogles 2007). We wanted to determine if PLD was involved in induction of 
DUSP5. 
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ETHANOL INHIBITION OF NPA MEDIATED INDUCTION OF DUSP5 AND 
DUSP4, BUT NOT DUSP1 
 
 
Exerimental Reasoning 
 
Treatment of DMS 53 cells with NPA resulted in increases in DUSP1, DUSP4 and 
DUSP5 mRNA expression were observed through real time PCR. Our overarching 
hypothesis is shown in Figure 1.2. Activation of the D2R receptor stimulates PLD 
activity. The PLD generated PA, possibly through the action of PLA2 results in the 
release of AA. The AA or a metabolite of AA is responsible for the changes in mRNA for 
the DUSPs. This change in expression of DUSPs results in the dephosphorylation of 
pERK and a resultant reduction in proliferation.   
  
We wanted to test if known inhibitors of the antiproliferative effect would also inhibit the 
increases in the mRNA of the DUSP family of genes. To this end, we selected two 
inhibitors of the D2R mediated signaling pathway (Figure 1.2). Phospholipase D has been 
demonstrated to mediate the antiproliferative effect in primary lactotrophs as well as in 
SCLC cell line, NCI-H69 (Senogles 2007). In order to determine if PLD was also 
involved in DUSP induction, ethanol was added to inhibit the generation of PA. As 
mentioned previously, PLD can use a primary alcohol as substrate with the generation of 
phosphatidylethanol instead of PA. The addition, of ethanol to DMS 53 cells, results in 
the inhibition of PA dependent downstream signaling. 
 
DMS53 cells were treated with 1 µM NPA, 1 µM NPA plus 0.5% ethanol or ethanol 
alone. NPA was added for 6 hours, while ethanol addition was delayed and remained on 
cells for the final 2 hours.   
 
 
Result of Ethanol Addition Experiment 
 
DUSP5  
 
Ethanol treatment of DMS 53 cells reduced the previously observed NPA induction of 
DUSP5 mRNA (Figure 3.10). The 0.28 fold induction (n=45, p<0.001) of DUSP5 by 
NPA was reduced 29% (n=51, p<0.05) to 0.20 fold above vehicle in conjunction with 
0.5% Ethanol addition to NPA. Ethanol alone did not affect significantly affect DUSP5 
expression compared to vehicle control (n=27, p=0.65). 
 
DUSP4 
 
NPA induced, DUSP4 (MKP-2) expression was minimal at 0.10 fold above vehicle 
(Figure 3.11), but statistically significant (n=23, p<0.05). This induction was completely 
abolished when Ethanol was added in conjunction with NPA (n=23, p<0.001). 
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Figure 3.10. Effect of Ethanol on DUSP5 Expression as Revealed by Real Time 
PCR.  DMS 53 cells were treated for  6 hour with 1 µM NPA, 1 µM NPA + 0.5% 
ethanol for 2hours or ethanol alone. All samples were standardized using 
cyclophilin D.  The fold change is calculated by taking the NPA treated samples 
divided by the vehicle.   A baseline of zero indicates no change compared to vehicle 
control. 
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Figure 3.11.  Effect of Ethanol on DUSP4 Expression as Revealed by Real Time 
PCR.  DMS 53 cells were treated for 6 hours with 1 µM NPA, 1 µM NPA + 0.5% 
ethanol for 2 hours or ethanol alone All samples were standardized using cyclophilin D.  
The fold change is calculated by taking the NPA treated samples divided by the vehicle. 
A baseline of zero indicates no change compared to vehicle control.
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DUSP1  
 
In contrast, the expression of DUSP1 mRNA (MKP-1) was increased by Ethanol as 
compared to vehicle control (Figure 3.12). Addition of Ethanol alone resulted in 0.37 fold 
increases of DUSP1 (n=25, p<0.001). As a result, the NPA induced DUSP1 expression 
was actually increased from 0.5 fold above vehicle (n=32, p<0.001) to 0.67 fold (n=46, 
p<0.001) compared to vehicle. This additional 25% induction of DUSP1 by Ethanol and 
NPA, reached marginal statistical significance of p<0.05. 
 
Other DUSP Family Members 
 
Addition of Ethanol alone had little effect on the expression of mRNA of other DUSPs 
tested (data not shown). The expression of DUSP3 mRNA was marginally reduced by 
ethanol alone (n=25, p<0.05), with a 0.19 decrease compared to vehicle control.  In 
addition Ethanol statistically increased DUSP9 mRNA expression by 0.15 fold. Neither 
DUSP2 (n=25, p=0.997), DUSP6 (n=27, p=0.84), DUSP7 (n=26, p=0.84) or DUSP14 
(n=7, p=0.97) mRNA expression were changed significantly by addition of Ethanol.  
 
 
Discussion of Ethanol Addition Experiment 
 
Ethanol inhibited the NPA induction of DUSP4 and DUSP5. Ethanol alone did not 
significantly effect the expression of either of these genes. The Ethanol and NPA 
combination did not result in reduced DUSP1 compared to levels seen in NPA treated 
cells. However, Ethanol alone did increase DUSP1 mRNA relative to vehicle control.  
For this reason we suspect that Ethanol related cellular stress activates another pathway.  
DUSP1 has little preference for JNK, p38 and ERK as substrates (Owens and Keyse 
2007). As a result, DUSP1 is involved in a large number of processes and has been 
shown to be rapidly induced by inflammatory stimuli (Wang 2007). As a result it is 
difficult to test how the inhibition of PA production through ethanol may affect the NPA 
induction of this gene. In other cell lines, ethanol treatment inhibits the antiproliferative 
effects of DA (Senogles 2007). This suggests that DUSP1 is not involved in this process, 
a hypothesis that is supported by the inability of NPA to induce MKP-1 (DUSP-1) 
through western blot. 
 
This collection of data suggests that DUSP 4 and 5 may be the phosphatases involved in 
the antiproliferative effect of D2R agonists. The expression of mRNA for both DUSP 4 
and 5 was sensitive to the presence of ethanol, which suggested that the mRNA for these 
proteins may be regulated by PLD. 
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Figure 3.12. Effect of Ethanol on DUSP1 Expression as Revealed by Real Time 
PCR. All samples were standardized using cyclophilin D.  The fold change is calculated 
by taking the NPA treated samples divided by the vehicle. A baseline of zero indicates no 
change compared to vehicle control. 
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INCREASED DUSP1, DUSP4 AND DUSP5 EXPRESSION FOLLOWING AA 
TREATMENT 
 
 
Experimental Reasoning 
 
AA involvement in the induction of DUSP1 (MKP-1), as observed by Metzler et al. 
1996, occurred in Vascular Smooth muscle cells. D2R potentiated AA release has been 
demonstrated in CHO (Piomelli 1991), lactotroph and SCLC cell lines (Senogles, 
unpublished observations).  In DMS 53 cells, we have observed D2R potentiated 
increases in several of the DUSPs. We wanted to determine if direct application of AA 
would generate similar changes in expression of these genes in DMS 53 cells as those 
observed with NPA treatment. AA, from Porcine Liver, Sodium Salt (Calbiochem) was 
stored in -20 C, dissolved in distilled-deionized water before adding to cells. AA was 
added to cells for 5 hours prior to lysis. 
 
 
Result of AA Treatment of DMS 53 Cells 
 
Significant concentration-dependant increases were seen in DUSP1 (MKP-1), DUSP4 
(MKP-2) and DUSP5 mRNA’s following the addition of AA. Note that these 
experiments are performed in the absence of NPA as we are evaluating the effects of AA 
alone. 
 
DUSP1  
 
Treatment of DMS 53 cells with AA resulted in an increase of expression for the mRNA 
for DUSP1 (MKP-1) compared to vehicle control levels (Figure 3.13). The increases in 
DUSP1 mRNA expression demonstrated concentration dependence up to 50 µM. 
Significant increases in mRNA for DUSP1 were observed with addition of 10 µM (0.22 
fold change, n=21, p<0.001), 50 µM (0.68 fold change, n=92, p<0.001) and 200 µM 
(0.53 fold change, n=15, p<0.001). At 1 µM concentration of AA, a minor inhibition of 
0.06 fold in mRNA expression was observed (n=30, p<0.001). 
 
DUSP4  
 
The addition of AA to DMS 53 cells resulted in significant increase of the mRNA for  
DUSP4 at 50 µM and 200 µM (Figure 3.14). The changes in DUSP4 were the strongest 
with 50 µM addition (0.33 fold increase, n=73, p<0.001) even more than those seen at 
200 µM (0.10 fold increase, n=21, p<0.001).  
 
DUSP5 
 
DUSP5 showed a dose dependence on AA concentration. The changes in mRNA 
observed gradually increased, with 0.16 fold increases seen at 10 µM AA addition.  The 
changes were larger (0.33 fold, n=74, p<0.001) at 50 µM and reached the 
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Figure 3.13. Effect of AA on DUSP1 Expression as Revealed by Real Time PCR 
Analysis. All samples were standardized using cyclophilin D.  The fold change is 
calculated by taking the NPA treated samples divided by the vehicle.  A baseline of zero 
indicates no change compared to vehicle control. 
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Figure 3.14. Effect of AA on DUSP4 Expression as Revealed by Real Time PCR 
Analysis. All samples were standardized using cyclophilin D. The fold change is 
calculated by taking the NPA treated samples divided by the vehicle. A baseline of zero 
indicates no change compared to vehicle control. 
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maximum of 0.58 fold (n=15) at 200 µM (Figure 3.15).   
 
Of the remaining DUSP genes, minimal changes in expression of mRNA were seen 
(Figure 3.16) and those changes were only seen at 200 µM for DUSP 3 (0.08 fold, 
p<0.01, n=15) at 50 µM for DUSP 9 (0.10, n=58, p<0.05) and DUSP 14 (0.08 fold, n=51, 
p<0.05).  No changes in expression of mRNA for DUSP7 expression were evident. 
 
 
Discussion of AA Treatment of DMS 53 Cells 
 
The addition of AA to DMS 53 cells resulted in significant changes in DUSP1 in as little 
as 10 µM and increased until 50 µM. Induction of DUSP1 at 200 µM fell slightly 
compared to those at 50 µM. This may indicate that some other factor is being changed at 
high concentrations. More likely however is that the difference between these two is an 
experimental difference. At 200 µM the number of trials was reduced, increasing the 
likelihood that greater variation may be seen. Increases in AA induced DUSP5 increased 
with concentration, reaching a maximum at 200 µM. These levels were markedly above 
the levels of increased mRNA expression seen by random experimental variation.  The 
results here suggest that AA does induce DUSP5. DUSP4 reached a maximum at 50 µM.  
At this concentration, the levels were above 0.30 fold change, approximately double 
those seen in genes with no change. At this concentration enough trials were performed 
to reduce unwanted statistical variation. Taken together these data suggest that AA 
induces mRNA expression of DUSP1, DUSP4 and DUSP5. 
 
Addition AA resulted in ablation of NPA induced DUSP mRNA. We were unsure exactly 
how PA may be leading to increased DUSP expression. Our overall hypothesis was that 
AA was being produced downstream of PA. The changes in expression induced by AA 
were similar in magnitude to the changes observed in response to NPA. In both 
experiments we witnessed the greatest changes in DUSP1 and DUSP5 with minor 
increases in DUSP4. This correlation suggests that AA may in fact be produced in 
response to NPA and this production may lead to the induction of DUSP1, DUSP4 and 
DUSP5. However, we have yet to establish that AA production as a result of DA 
signaling actually led to the induction of the mRNA of these three genes. We sought to 
inhibit the actions of AA following NPA addition and then evaluated the induction of 
these genes. 
 
 
REDUCTION OF  DUSP1, DUSP4 AND DUSP5 INDUCTION BY NPA 
FOLLOWING ADDITION OF AA INHIBITORS 
 
 
Experimental Reasoning 
 
As shown in the previous section, AA alone would bring about changes in the mRNA 
expression for a number of DUSPs. Our hypothesis is that if NPA induced expression of 
DUSPs is AA dependent, an inhibitor of AA should block the changes in mRNA 
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Figure 3.15.  Effect of AA on DUSP5 Expression as Revealed by Real Time PCR 
Analysis. All samples were standardized using cyclophilin D.  The fold change is 
calculated by taking the NPA treated samples divided by the vehicle.  A baseline of zero 
indicates no change compared to vehicle control. 
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Figure 3.16.  Effect of AA on DUSP Expression as Revealed by Real Time PCR 
Analysis. All samples were standardized using cyclophilin D.  The fold change is 
calculated by taking the NPA treated samples divided by the vehicle.  A baseline of zero 
indicates no change compared to vehicle control. 
 
 
observed with AA. For this reason, we chose to investigate the effects of ETYA on 
expression of DUSPs by real time PCR. 
 
5,8,11,14-eicosatetraynoic acid (ETYA) is a cell permeable and nonhydrolyzable analog 
of AA (5,8,11,14-eicosatetraenoic acid), which competitively inhibits AA (Ondrey 1989; 
Taylor 1985). ETYA has been shown to inhibit phospholipase A2 (PLA2) and 
cytochrome P-450. In addition, it has also been shown to inhibit cyclooxygenase, 5-
lipoxygenase, 12-lipoxygenase and 15-lipoxygenase (Ekokoski 1994; Honda 1999; 
Ondrey 1989).  
 
NPA was added to all conditions at a concentration of 1 µM.  ETYA was dissolved in 
DMSO and added to culture media at a final concentration of 10 µM ETYA and 0.01%  
DMSO. The conditions for treatment were NPA or NPA with ETYA/DMSO or DMSO 
alone. Each well of a six well cluster dish corresponded to one condition: NPA alone, 
NPA plus ETYA/DMSO or NPA plus DMSO alone and cells were allowed to incubate in 
normal culture conditions for 4 hours. At the end of the test period, media was aspirated, 
cells were washed and RNA extracted as described in methods. 
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Result of ETYA Addition to DMS 53 Cells 
 
DUSP1 
 
As confirmation of previous results, NPA increased DUSP1 expression 0.72 fold above 
vehicle control (n=42, p<0.001) as shown in Figure 3.17.  The addition of 10 µM ETYA 
in 0.01% DMSO reduced the mRNA for DUSP1 by 46% compared to NPA alone, and 
0.39 fold compared to the DMSO vehicle (n=60, p<0.001). The changes in DUSP 
expression were not a result of DMSO present in the media as DMSO alone did not 
significantly change NPA induced DUSP1 expression resulting in 0.65 fold increase over 
vehicle (n=30, p=0.38).  
 
DUSP5 
 
Addition of NPA alone resulted in a 0.45 fold increase in DUSP5 mRNA expression over 
vehicle control. This increase in expression by NPA was ablated by 56.5% 
with the inclusion of ETYA compared to vehicle (n=48, p<0.001). The addition of 
DMSO (0.341 fold, n=36, p=0.16) did not significantly inhibit DUSP5 mRNA induction 
by NPA (Figure 3.18). 
 
 
 
 
 
Figure 3.17.  Effect of 10 µM ETYA Added to 1 µM NPA Treatment on DUSP1 as 
Revealed by Real Time PCR. Fold change is calculated relative to vehicle control.  
Significance levels in the upper portion of the graph represent the comparison of NPA 
alone to the other treatment conditions. 
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Figure 3.18.  Effect of 10 µM ETYA Added to 1 µM NPA Treatment on DUSP5 as 
Revealed by Real Time PCR. Fold change is calculated relative to vehicle control.  
Significance levels in the upper portion of the graph represent the comparison of NPA 
alone to the other treatment conditions. 
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DUSP4 
 
While the addition of NPA increased the expression of mRNA for DUSP4 (MKP-2) 0.23 
fold compared to control (n=36, p<0.001), these changes were similar to those seen 
overall (Figure 3.19). The induction of DUSP 4 mRNA by NPA was completely 
abolished by ETYA (n=54, p<0.001) and registered a reduction of mRNA expression by 
0.21 fold compared to vehicle (p<0.001). 
 
 
Discussion of ETYA Addition to DMS 53 Cells 
The addition of ETYA resulted in complete inhibition of NPA mediated increases in 
DUSP4 and partial inhibition of increases in DUSP1 and DUSP5. DMSO as a vehicle did 
not have any effect on the NPA induction of these genes. These results indicate that AA 
is involved in the NPA induction of these genes. Following the induction of these DUSPs 
with external application of AA, we expected DUSP4 and DUSP5 to be inhibited by 
ETYA. The induction of both of these genes appeared to be dependent on PA as indicated 
by the inhibition with ethanol. Our expectation was that PA produced would be 
metabolized to AA. 
 
 47
 
 
 
Figure 3.19.  Effect of 10 µM ETYA Added to 1 µM NPA Treatment on DUSP4 
Expression as Revealed by Real Time PCR.  Fold change is calculated relative to 
vehicle control.  Significance levels in the upper portion of the graph represent the 
comparison of NPA alone to the other treatment conditions. 
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CHAPTER 4. SUMMARY/CONCLUSION 
 
 
Our overarching hypothesis was that the D2R dopamine receptor mediated signaling 
impacted the expression of DUSP family of proteins.  We hypothesized that the D2R 
receptor, through stimulation of PLD and generation of PA, would impact DUSP 
expression.  The proposed pathway suggests that PA may be metabolized through the 
action of cPLA2 to generate AA.  AA generated in this method might directly or 
indirectly lead to increased DUSP mRNA, followed by greater protein levels and 
phosphatase activity generated toward ERK. 
 
Our first step to evaluate this hypothesis was to confirm D2R mediated antiproliferation 
in DMS53 cells.We observed modest reductions in proliferation through the cyquant NF 
proliferation assay, which is based on DNA content of cells. We concluded that in this 
SCLC cell line that NPA would result in a reduction in proliferation. This effect has been 
observed by our laboratory in other SCLC cell lines as well as GH4C1 and HEK cells 
transfected with the cDNA of the D2R. Next we sought to determine if expression of any 
DUSP genes were increasing following D2R stimulation. We chose to use RT-PCR for 
this set of experiments. The primary reason for this choice was that we could we could 
evaluate a number of DUSP genes simultaneously. Primers for DUSP1, 2, 4, 5, 6, 7 and 
14 were validated and expression levels were determined through real time PCR analysis.  
We evaluated gene expression for each of these genes in the presence and absence of 
NPA and found a number of changes. Addition of NPA resulted in significant increases 
in the expression of DUSP1 (MKP-1), DUSP4 (MKP-2) and DUSP5 mRNA. We 
observed increases in all three genes at the two and six hour time points. Insignificant 
levels of the remaining DUSPs demonstrated the experimental variation involved in the 
real time PCR and indicated the sensitivity of the assay. Changes following addition of 
NPA of the mRNA for DUSP4 and DUSP14 were in the range that we believed to be due 
to experimental variability as determined by evaluating how genes with no statiscal 
significance varied positively and negatively inside this range. As changes in expression 
for these genes were inside this range, we had reason to expect type one statistical errors 
even though statistical significance was reached. NPA consistently induced changes in 
DUSP4 in each experiment where NPA induction was used as a positive control. In 
addition, we had previously seen NPA induced changes in MKP-2 (DUSP4) in other 
SCLC cell lines, leading us to believe that the modest NPA induced changes in DUSP4 
mRNA may contribute to changes in protein levels. While the DUSP4 levels were 
modest, DUSP1 and DUSP5 were induced at the highest levels of significance and 
approximately three times the experimental variation. 
 
Next, we wanted to determine the signaling pathway leading to increased DUSP1, 
DUSP4 and DUSP5 expression.  We tested whether NPA induced expression of these 
genes could be inhibited by inhibiting PA production, using ethanol. Ethanol inhibited 
NPA induction of DUSP4 and DUSP5, but not DUSP1. Ethanol reduced NPA mediated 
increase in DUSP5 nearly thirty percent and completely abolished the NPA mediated 
increase in DUSP4.  As a surprise, when added to NPA treated cells, 0.5% Ethanol, 
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actually increased DUSP1 expression. The induction of DUSP1 by ethanol was also 
observed in the absence of NPA. 
 
We wanted to determine how PA generated through PLD might lead to induction of these 
genes.  We hypothesized that DUSP induction might occur through the metabolism of PA 
and eventual production of AA.  Real time PCR revealed dose dependent, AA induced 
increases in mRNA for DUSP1, DUSP4 and DUSP5 which mimicked the changes 
induced by NPA. At similar levels, DUSP1, DUSP4 and DUSP5 were increased by 
treatment with AA. These results confirmed that mRNA for these genes was increased 
through external application of AA.  Inhibitors of the action of AA, such as ETYA were 
used to determine if they could block the effects of NPA.  The NPA mediated increases 
in all three of these genes were inhibited by treatment with ETYA.  NPA induced 
significant increases in DUSP1, DUSP4 and DUSP5. ETYA reduced or eliminated the 
increases due to NPA addition of all three of these DUSP genes. DMSO as a vehicle did 
not significantly decrease any of the three genes. 
 
Taken together, this information suggests the following conclusion.  Expression of 
DUSP1, DUSP5 and DUSP4 expression levels are mediated by the D2R, activated by 
NPA. The role of PLD has been shown as ethanol will ablate the changes in mRNA 
observed with NPA treatment. In addition, treatment of DMS 53 cells with exogenous 
AA mimics the effects observed with D2R agonist. These data are consistent with a 
model in which D2R agonists stimulate PLD, resulting in the release of PA which is 
metabolized to AA. In turn, AA either directly or through a metabolite, brings about the 
increases in DUSP mRNA. 
 
DUSP5 is the strongest candidate as the phosphatase responsible for the 
dephosphorylation of ERK in the D2R mediated antiproliferative effect. Western Blot for 
DUSP5 show subsequent changes in protein levels following NPA stimulation. Of the 
nuclear inducible DUSPs, DUSP5 is also the most specific toward ERK (Owens and 
Keyse 2007).  Increased DUSP5 has been shown to bind ERK, inactivate it through 
dephosphorylation and anchor it in the nucleus, thus preventing ERK from being 
phosphorylated again (Keyse 2005).  However, it should not be ruled out that these 
DUSP genes are working in concert to reduce ERK phosphorylation as each of these 
genes code for proteins which exhibit some phosphatase activity toward ERK (Owens 
and Keyse 2007). 
 
We hypothesize that these changes occur through the following pathway (Figure 4.1). 
Treatment of DMS 53 cells with NPA results in the stimulation of PLD and the 
production of PA.  Ethanol inhibition of NPA stimulated expression of DUSP5 and 
DUSP4 suggests the induction of these genes is dependant on PA released from PLD 
activity.  Metabolism of PA through unverified mechanisms generates AA.  AA 
generated from PA induces RNA expression of DUSP1 (MKP-1), DUSP4 and DUSP5 
through unknown molecular mechanisms.  The increased DUSP5 mRNA results in 
increased protein which binds and dephosphorylates ERK. 
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Figure 4.1. Proposed Mechanism for D2R Mediated Antiproliferation. D2R binding 
indirectly activates PLD, which catalyzes the conversion of PC to PA.  PA is metabolized 
through unverified pathways leading to AA release.  AA leads to increased DUSP5 
mRNA and protein. DUSP5 binds phosphorylated ERK and dephosphorylates ERK. 
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The information generated from these experiments answers some questions while others 
are unanswered. AA dependent DA induction of DUSP4 and DUSP5 correlates with 
changes in proliferation. Logically, DUSP induction would lead to reduction of pERK 
and subsequently reduce proliferation.  Several experiments remain to ensure that all of 
the events in this thesis are directly connected. However, this information lends support 
to the hypothesis that PLD is activated leading to AA release and subsequent changes in 
DUSP5 and DUSP4 through unknown mechanisms. 
 
Further investigation is required to determine whether DUSP expression directly 
influences changes in ERK phosphorylation and activity and subsequent changes in 
proliferation. We observed D2R mediated changes in ERK phosphorylation and also 
increased DUSP5 immunoreactivity.  It has been reported that DUSP5 can anchor in the 
nucleus and reduce phosphorylation of ERK (Keyse 2005). Ultimately, we would like to 
evaluate the cellular consequences of inhibiting DUSP5 specifically. However, DUSP5 
specific inhibitors are not yet designed.  Employing other technologies such as siRNA to 
knockout DUSP5 and determining the effect on NPA reduction in proliferation and ERK 
phosphorylation would allow us to determine if DUSP5 is sufficient to inhibit these 
effects. This knockout also would answer questions or whether DUSP5 resides upstream 
of ERK in the antiproliferative pathway. 
 
Another question still left unanswered is the mechanism through which AA is generated 
in this pathway.  In our hypothesis there are two possible methods whereby PA might be 
metabolized to AA (Figure 1.2). AA release is primarily a result of cytosolic 
Phospholipase A2 (Lin 1992).  If D2R receptor mediated DUSP expression is PLA2 
dependent, this expression should be inhibited by PLA2 inhibitors. 
 
In addition, questions remain about the discrepancies between the DUSP1 and the 
DUSP4/DUSP5 induction by NPA. Ethanol may be inducing DUSP1 through a separate 
mechanism. DUSP1 is largely involved in JNK expression. Ethanol may induce cellular 
stress which is sufficient to induce JNK and DUSP1 expression is induced by JNK as a 
feedback mechanism.  DUSP1 induced through this pathway. Alternatively, PLD activity 
may lead to localized concentrations of AA which generate changes in DUSP4 and 
DUSP5, but do not effect on DUSP1 induction.   
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